The UK market for "Hormones in Dosage Except Contraceptives and Antibiotics" experienced a consistent decline from 2013 to 2023, with the total market value dropping from $7.4679 billion in 2013 to $2.9947 billion in 2023. The market saw significant decreases from 2014 to 2017, with a slight recovery in 2018, before continuing its downward trajectory. The year-on-year declines in 2022 and 2023 were 14.59% and 6.31%, respectively, showcasing a persistent decline. The 5-year CAGR from 2018 to 2023 was -6.03%, indicating an average yearly contraction.

Future trends to watch for in this market include:

Advancements in hormone therapy which might drive innovation and growth within specific niches.
Potential regulatory changes affecting production and distribution, especially in post-Brexit UK.
Shifts in public health policies and healthcare priorities, which could influence market demand.
Emerging competition from alternative therapies, impacting market share for traditional hormone dosage products.
The potential impact of global supply chain disruptions on production and pricing.